@article{18faf54a4448459ab1b4205f61dbd508,
title = "Striatopallidal adenosine A2A receptor modulation of goal-directed behavior: Homeostatic control with cognitive flexibility",
abstract = "Dysfunction of goal-directed behaviors under stressful or pathological conditions results in impaired decision-making and loss of flexibility of thoughts and behaviors, which underlie behavioral deficits ranging from depression, obsessive-compulsive disorders and drug addiction. Tackling the neuromodulators fine-tuning this core behavioral element may facilitate the development of effective strategies to control these deficits present in multiple psychiatric disorders. The current investigation of goal-directed behaviors has concentrated on dopamine and glutamate signaling in the corticostriatal pathway. In accordance with the beneficial effects of caffeine intake on mood and cognitive dysfunction, we now propose that caffeine's main site of action - adenosine A2A receptors (A2AR) - represent a novel target to homeostatically control goal-directed behavior and cognitive flexibility. A2AR are abundantly expressed in striatopallidal neurons and colocalize and interact with dopamine D2, NMDA and metabotropic glutamate 5 receptors to integrate dopamine and glutamate signaling. Specifically, striatopallidal A2AR (i) exert an overall “break” control of a variety of cognitive processes, making A2AR antagonists a novel strategy for improving goal-directed behavior; (ii) confer homeostatic control of goal-directed behavior by acting at multiple sites with often opposite effects, to enhance cognitive flexibility; (iii) integrate dopamine and adenosine signaling through multimeric A2AR-D2R heterocomplexes allowing a temporally precise fine-tuning in response to local signaling changes. As the U.S. Food and Drug Administration recently approved the A2AR antagonist Nourianz{\textregistered} (istradefylline) to treat Parkinson's disease, striatal A2AR-mediated control of goal-directed behavior may offer a new and real opportunity for improving deficits of goal-directed behavior and enhance cognitive flexibility under various neuropsychiatric conditions.",
keywords = "Adenosine A receptor, Cognitive flexibility, Goal-directed behavior, Habit, Homeostasis, Striatopallidal neurons",
author = "Chen, {Jiang Fan} and Choi, {Doo Sup} and Cunha, {Rodrigo A.}",
note = "Funding Information: JFC is supported by the National Natural Science Foundation of China (Grant #81630040 and #31771178) , the State Department of Science and Technology of China ( 2016YFC1306600 ) and the Start-up Fund from Wenzhou Medical University (nº 89212012 ); DSC is supported by the Samuel C. Johnson for Genomics of Addiction Program at Mayo Clinic , the Ulm Foundation of USA , National Institute on Alcohol Abuse and Alcoholism of USA ( R01 AA018779 ); RAC is supported by La Caixa Foundation of Spain ( LCF/PR/HP17/52190001 ), Centro 2020 of Portugal ( CENTRO-01-0145-FEDER-000008 :BrainHealth 2020 and CENTRO-01-0246-FEDER-000010 ) and FCT of Portugal ( POCI-01-0145-FEDER-03127 ). JFC declares no biomedical financial interests or potential conflicts of interest. RAC is a scientific consultant of the Institute for Scientific Information on Coffee (ISIC) and DSC is a scientific advisory board member to Peptron Inc. And these entities had no role in preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication. Funding Information: JFC is supported by the National Natural Science Foundation of China (Grant #81630040 and #31771178), the State Department of Science and Technology of China (2016YFC1306600) and the Start-up Fund from Wenzhou Medical University (nº 89212012); DSC is supported by the Samuel C. Johnson for Genomics of Addiction Program at Mayo Clinic, the Ulm Foundation of USA, National Institute on Alcohol Abuse and Alcoholism of USA (R01 AA018779); RAC is supported by La Caixa Foundation of Spain (LCF/PR/HP17/52190001), Centro 2020 of Portugal (CENTRO-01-0145-FEDER-000008:BrainHealth 2020 and CENTRO-01-0246-FEDER-000010) and FCT of Portugal (POCI-01-0145-FEDER-03127). JFC declares no biomedical financial interests or potential conflicts of interest. RAC is a scientific consultant of the Institute for Scientific Information on Coffee (ISIC) and DSC is a scientific advisory board member to Peptron Inc. And these entities had no role in preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
month = mar,
day = "15",
doi = "10.1016/j.neuropharm.2023.109421",
language = "English (US)",
volume = "226",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
}